This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Oppenheimer, E. Articles by Cohen, S. Search for Related Content PubMed PubMed Citation Articles by Oppenheimer, E. Articles by Cohen, S. Social Bookmarking                         What's this?

A Preclinical Study ofEO-122, a New Lidocaine- Like Antiarrhythmic Drug

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, and the Intensive Care Unit, Meir Hospital, Kfar Saba, Israel

Eliezer Kaplinsky

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, and the Intensive Care Unit, Meir Hospital, Kfar Saba, Israel

Naam Kariv

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, and the Intensive Care Unit, Meir Hospital, Kfar Saba, Israel

Rachel Bruckstein

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, and the Intensive Care Unit, Meir Hospital, Kfar Saba, Israel

Sasson Cohen

Department of Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, and the Intensive Care Unit, Meir Hospital, Kfar Saba, Israel

The 2,6-dimethylanilide of quinuclidine-3-carboxylic acid hydrochloride (EO-122), a new structural analog of lidocaine, has been shown to possess po tent antiarrhythmic activity in experimentally induced arrhythmias in animals. Restoration of normal sinus rhythm and suppression of ouabain-induced ar rhythmia in cats and dogs, and of coronary occlusion-induced arrhythmia in dogs, followed a single IV injection of 1-3 mg/kg, with an onset of 2 minutes and a duration of 20-240 minutes. Occlusion-induced arrhythmia was likewise suppressed after an oral dose of 10-20 mg/kg, with an onset of 11-65 minutes and a duration of 25-120 minutes. Under similar conditions, lidocaine was ei ther totally ineffective or of ultra-short duration.

The bioavailability of EO-122 by the oral route exceeded 80% of the oral dose. Therapeutic blood concentrations were in the range 0.5-7 µg/ml. At about 5µg/ml there was a slight depression of cardiac function in the anesthe tized cat, but not in the conscious dog. In cats, complete A-V block occurred at concentrations of 60-70 µg/ml. The IV LDso in mice was 22 mg/kg, and in rabbits 8.5 mg/kg. No overt signs of neurotoxicity could be observed at any dose of EO-122. The pharmacokinetic profile of the drug fits a two-com partment open model, with t 150 min and V_d (ss) 1.5 1/kg.

Angiology, Vol. 31, No. 6, 410-426 (1980)
DOI: 10.1177/000331978003100605


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?